Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges
Hugo Geerts(Certara (United States)), Mary Ann Pelleymounter(Amgen (United States)), Susanne E. Swalley(Biogen (United States)), David A. Bennett(Rush University Medical Center), Rima Kaddurah‐Daouk(Duke University), John P. Wikswo(Vanderbilt University), Chris Gaiteri(Rush University Medical Center), Piet H. van der Graaf(Pfizer (United Kingdom)), Katya Tsaioun(Johns Hopkins University), Jane P. F. Bai(United States Food and Drug Administration), Edgar Schuck(Eisai (United States))
Cited by 51
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Effects of the <i>obese</i> Gene Product on Body Weight Regulation in <i>ob</i> / <i>ob</i> Mice
|Science|1995|4k
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
|Neurology|2016|1.9k
Gene expression elucidates functional impact of polygenic risk for schizophrenia
|Nature Neuroscience|2016|1.2k